New EMT antibody panel is released
New EMT antibody panel is released
Epithelial-mesenchymal transition (EMT) is a process by which polarized epithelial cells are transformed into mesenchymal cells and shows reduced cell adhesion, increased motility and invasive properties. EMT is a key driver of cancer metastasis. Targeting EMT in cancer cells has become an aim of pharmaceutical development.
arigo is proud to introduce the newly launched EMT antibody panel (ARG30320) which is ideal to facilitate EMT-related studies.
EMT antibody panel (ARG30320)
| Component | Clonality | Reactivity | Application | Package |
| E-Cadherin antibody [SQab1717] | Rabbit mAb | Hu | IHC-P, WB | 20 ul |
| Vimentin antibody [SQab1721] | Rabbit mAb | Hu, Ms | FACS, ICC/IF, IHC-Fr, IHC-P, IP, WB | 20 ul |
| N-Cadherin antibody | Rabbit pAb | Hu, Ms, Rat, Sh | ELISA, FACS, ICC/IF, IHC-P, IP, WB | 20 ul |
| GAPDH antibody [SQab1878] | Rabbit mAb | Hu, Ms, Rat, Bo, Ch, Mk, Pig, Xl, Zfsh |
FACS, ICC/IF, IHC-P, IP, WB | 20 ul |
| anti-Rabbit IgG antibody (HRP) | Goat pAb | Rb | ELISA, IHC-P, WB | 50 ul |
Benefits
* Includes both epithelial and mesenchymal markers
* Includes the most suitable loading control
* Includes secondary antibody
* Comprises antibodies with good performance
|
E-Cadherin antibody [SQab1717]
|
 |
|
|
 |
|
|
 |
